Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio Inc (ANAB) is a clinical-stage biotechnology company developing antibody therapeutics for autoimmune and inflammatory diseases. Track ANAB news to monitor clinical trial updates, regulatory milestones, corporate development activities, and strategic initiatives affecting this San Diego-based immunology-focused biotech.
AnaptysBio's news flow typically centers on clinical trial announcements, including patient enrollment updates, data readouts from ongoing studies, and initiation of new Phase 2 or Phase 3 programs. For biotech investors, these clinical milestones represent key value drivers that can significantly impact the company's valuation as drug candidates progress through development stages. The company also announces regulatory interactions, including FDA meeting outcomes and submissions of investigational new drug applications.
Beyond clinical development, ANAB generates news through corporate transactions and capital allocation decisions. Stock repurchase programs, equity financings, strategic partnerships, and business combination discussions all create newsworthy events that affect shareholders. The company periodically announces litigation matters, licensing agreements, and intellectual property developments that shape its competitive position in the antibody therapeutics space.
Financial results represent another major news category, with quarterly earnings reports providing updates on cash runway, research and development spending, and progress across the therapeutic pipeline. Participation in investor conferences and industry presentations offers additional insight into management's strategic priorities and development timelines. For investors tracking immunology-focused biotechnology companies, following AnaptysBio's news stream provides essential context for understanding how the company's clinical programs advance and how management deploys capital to maximize the probability of regulatory success.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast will be available on the company's investor site at https://ir.anaptysbio.com/presentations-and-events, with a replay available for at least 30 days after the event.
Vanda Pharmaceuticals (Nasdaq: VNDA) submitted a Biologics License Application (BLA) to the FDA on Dec 15, 2025 for imsidolimab to treat generalized pustular psoriasis (GPP).
The BLA is supported by positive global Phase 3 GEMINI-1 and GEMINI-2 results: a single intravenous dose produced rapid clearance (clear or almost clear skin) with efficacy maintained during an approximately 2-year maintenance period with monthly dosing, and a favorable safety profile with no clinically meaningful safety signals reported. Vanda requested priority review, which could enable FDA action as early as mid-2026 if granted.
Anaptys (Nasdaq: ANAB) said CEO Daniel Faga and other executives will participate in multiple December investor conferences, including a fireside chat and 1x1 meetings at the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 1:30 PM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 3, 2025 at 7:55 AM ET.
Live webcasts of the fireside chats will be available on the company investor website and replays will be available for at least 30 days after each event.
Anaptys (Nasdaq: ANAB) announced an amended $100.0 million stock repurchase plan, in addition to $6.4 million remaining under the prior $75.0 million plan.
The company previously repurchased 3,443,188 shares, equal to 11.2% of shares outstanding before that repurchase program. Purchases may occur in open market transactions or under Rule 10b5-1/10b-18 programs.
Anaptys expects to end 2025 with approximately $300 million in cash, cash equivalents and investments, which includes an anticipated one-time $75 million commercial sales milestone from GSK tied to Jemperli reaching $1 billion in worldwide net sales. The repurchase plan expires March 31, 2026 and may be suspended or discontinued at any time; it does not obligate any repurchases.
Anaptys (Nasdaq: ANAB) reported that its Phase 2 trial of rosnilimab in moderate-to-severe ulcerative colitis did not meet the Week 12 primary endpoint (mean change in modified Mayo Score) or key secondary endpoints of clinical response and remission; the UC trial will be discontinued.
Rosnilimab was well tolerated with no new safety signals and showed ~90% depletion of pathogenic T cells in blood and PD-1+ T cell depletion in colon at Week 12. Discontinuing UC will save at least $10 million. Company expects to end 2025 with approximately $300 million, including a one-time $75 million GSK milestone in Q4 2025 tied to Jemperli sales, and plans to pursue rosnilimab in RA with an H1 2026 update and to separate biopharma operations from royalty assets in 2026.
Anaptys (NASDAQ: ANAB) said CEO Daniel Faga and other executives will participate in multiple investor conferences in November 2025, including TD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 8:00 AM ET, Guggenheim Healthcare Innovation Conference (Boston) on Nov 12, 2025 at 11:30 AM ET, Stifel Healthcare Conference (New York) on Nov 13, 2025 at 1:20 PM ET, and Jefferies Global Healthcare Conference (London) on Nov 17, 2025 at 4:00 PM GMT.
Live webcasts and replays (available for at least 30 days) will be posted on Anaptys’ investor presentations and events page.
Anaptys (Nasdaq: ANAB) reported Q3 2025 results and announced intent to separate its biopharma operations from its royalty management business by year-end 2026 to unlock value across two public companies. The company expects to accrue a one-time $75 million commercial milestone in Q4 2025 when GSK's Jemperli reaches $1 billion in worldwide sales and cites >$390 million in annualized royalties at GSK peak-sales guidance of >$2.7 billion.
Operationally, Anaptys highlighted rosnilimab Phase 2b RA data and expects top-line Week-12 UC Phase 2 data in Nov/Dec 2025; ANB033 Phase 1b in celiac initiated with data expected in Q4 2026. Cash and investments were $256.7 million at Sept 30, 2025, with ~3.34M shares repurchased (~10.9% outstanding) for $65.2 million.
Anaptys (Nasdaq: ANAB) reported late-breaking Phase 2b results for rosnilimab in rheumatoid arthritis on Oct 29, 2025, from a global 424-patient trial presented at ACR Convergence 2025. Primary Week 12 efficacy on DAS28-CRP and ACR20 was confirmed and responses deepened by Week 28, including CDAI low disease activity and CDAI remission, independent of prior advanced therapies including JAK inhibitors.
Responses remained durable for at least three months off drug. Safety through Week 38 showed rosnilimab was well-tolerated with no treatment-related serious adverse events, no malignancies, and no deaths; Tph cells were reduced by >90% by Week 6.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
